Prostate Cancer Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 150+ Companies Working in the Domain
October 15, 2024 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Prostate Cancer Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 150+ Companies Working in the...
Radiopharmaceuticals Market Size Projected to Soar to USD 16.6 Billion by 2032 with 10.4% CAGR – SNS Insider
October 04, 2024 09:00 ET
|
SNS Insider pvt ltd
Pune, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Radiopharmaceuticals Market Analysis: According to SNS Insider, the Radiopharmaceuticals Market Size was estimated at USD 5.0 billion in 2023 and is...
Curium Công bố Quan hệ Đối tác Chiến lược với PeptiDream nhằm phát triển Đồng vị phóng xạ trong Chuẩn trị ung thư tuyến tiền liệt tại Nhật Bản
October 02, 2024 11:01 ET
|
Curium US LLC
Nội dung hợp tác bao gồm phát triển lâm sàng, hoàn thành hồ sơ pháp lý, và thương mại hóa các sản phẩm tại Nhật 177Lu-PSMA-I&T và 64Cu-PSMA-I&TXây dựng trên nền tảng quan hệ bên vững giữa hai...
Curium ประกาศความร่วมมือเชิงกลยุทธ์กับ PeptiDream สำหรับผลิตภัณฑ์รักษามะเร็งต่อมลูกหมากในญี่ปุ่น
October 02, 2024 11:01 ET
|
Curium US LLC
โดยเป็นความร่วมมือเพื่อพัฒนาทางคลินิก การยื่นเรื่องต่อหน่วยงานกำกับดูแล และการนำ 177Lu-PSMA-I&T และ 64Cu-PSMA-I&T...
핵의학 기업 Curium, 일본의 전립선암 테라노스틱 분야 공동 개발 위해 PeptiDream과 전략적 파트너십 체결
October 02, 2024 11:01 ET
|
Curium US LLC
177Lu-PSMA-I&T 및 64Cu-PSMA-I&T 의 일본 내 임상 개발, 규제 신청 및 상용화 추진 과정에서의 협력 포함양사 간 오랜 기간 형성된 관계를 바탕으로 파트너십 구축일본의 전립선암 신규 진단건수 매년 약 9만 건 수준 파리, Oct. 03, 2024 (GLOBE NEWSWIRE) -- 핵의학 부문을 선도하는...
Curium Mengumumkan Perkongsian Strategik dengan PeptiDream untuk Teranostik Kanser Prostat di Jepun
October 02, 2024 11:01 ET
|
Curium US LLC
Kolaborasi untuk menyertakan pembangunan klinikal, pemfailan kawal selia dan pengkomersialan di Jepun bagi 177Lu-PSMA-I&T dan 64Cu-PSMA-I&TDibina berdasarkan hubungan yang sudah lama terjalin...
Curium Mengumumkan Kemitraan Strategis dengan PeptiDream untuk Teranostik Kanker Prostat di Jepang
October 02, 2024 11:01 ET
|
Curium US LLC
Kerja sama mencakup pengembangan klinis, pengajuan regulasi, dan komersialisasi di Jepang untuk 177Lu-PSMA-I&T dan 64Cu-PSMA-I&TDibangun di atas hubungan yang telah terjalin lama antara kedua...
Curium 宣布與 PeptiDream 建立策略夥伴關係，在日本前列腺癌治療學領域展開合作
October 02, 2024 11:01 ET
|
Curium US LLC
合作內容包括 177Lu-PSMA-I&T 和 64Cu-PSMA-I&T 在日本的臨床開發、監管備案和商業化工作基於兩間公司的長期合作關係日本每年有大約 9 萬宗前列腺癌新病例確診 巴黎, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Curium 是一家世界領先的核醫學企業，今天宣布與 PeptiDream 的全資子公司...
Curium 宣布与 PeptiDream 达成战略合作，在日本开展前列腺癌诊疗一体化项目
October 02, 2024 11:01 ET
|
Curium US LLC
此次合作将涵盖在日本开展的 177Lu-PSMA-I&T 和 64Cu-PSMA-I&T 的临床开发、监管备案及商业化进程这一合作建立在两家公司长期以来的紧密关系之上在日本，每年约有 90,000 例新诊断的前列腺癌病例 巴黎, Oct. 02, 2024 (GLOBE NEWSWIRE) -- 全球核医学领域的领先企业 Curium 今日宣布与 PeptiDream...
Curium מכריזה על שותפות אסטרטגית עם PeptiDream לטיפול ממוקד מטרה בסרטן הערמונית ביפן
October 02, 2024 11:01 ET
|
Curium US LLC
*שיתוף פעולה שיכלול פיתוח קליני, הגשה רגולטורית ומסחור ביפן של 177Lu-PSMA-I&T ו- 64Cu-PSMA-I&T *מתבסס על מערכת יחסים ארוכת שנים בין שתי החברות *ביפן מאובחנים מדי שנה כ-90,000 מקרים חדשים...